摘要
目的采用网络药理学方法探索冠心舒通胶囊治疗冠心病的"多成分-多靶点-多通路"网络调控机制。方法基于液质联用技术从冠心舒通胶囊中辨识其化学物质组成,以口服生物利用度(OB)≥30%和类药性(DL)≥0. 18筛选活性成分,进一步利用中药系统药理学数据库和分析平台(traditional Chinese medicine systems pharmacology,TCMSP)预测活性成分的作用靶点,并与通过文献挖掘及多种数据库搜寻的冠心病相关靶点进行比对,筛选冠心舒通胶囊治疗冠心病的关键靶点,最后借助于生物分子功能注释系统3. 0(Molecule Annotation System 3. 0,MAS 3. 0)对得到的关键靶点进行通路注释分析。结果基于液质联用技术辨识指认得到43个化合物;通过OB及DL筛选得到鞣花酸、隐丹参酮、丹参酮ⅡA等10个主要活性成分;这些成分可作用于CLP、LDLR、TNF等关键靶点26个,共涉及49条重要信号通路(P <0. 05)。结论冠心舒通胶囊可能主要通过对TGF-beta、T细胞受体、MAPK等信号通路的干预来发挥治疗冠心病的作用,体现了冠心舒通胶囊多成分、多靶点、多途径的作用特点,为进一步深入揭示冠心舒通胶囊治疗冠心病的作用机制奠定了一定基础。
OBJECTIVE To explore the ' multi-component,multi-target,multi-pathway' network regulation mechanism of Guanxinshutong caspules( GXST) in treatment of coronary heart disease by network pharmacology method. METHODS The chemical components of GXST were identified based on liquid chromatography-mass spectrometry( LC-MS),and the oral bioavailability( OB) ≥30 % and drug likeness( DL) ≥0. 18 were used as the screening conditions for obtaining active molecular compounds. The targets related to the active compounds were predicted through the Traditional Chinese Medicine Systems Pharmacology database( TCMSP). The relevant targets of coronary heart disease were searched through literature mining and multiple databases and compared with the predicted component targets. Finally,the targets were introduced into the Molecule Annotation System 3. 0( MAS 3. 0) to analyze the main biological pathways. RESULTS Forty-three compounds were identified in GXST based on LC-MS technology and 10 main active compounds were determined through OB and DL screening,such as ellagic acid,cryptotanshinone,and tanshinone. These components affected 26 key targets,such as CLP,LDLR,TNF,et al,and 49 KEGG pathways were involved( P < 0. 05). CONCLUSION GXST produces therapeutic effect for coronary heart disease mainly through the TGF-beta,T cell receptors,and MAPK signaling pathway. This study further reveals the characteristics of the multicomponent,multi-target and multi-pathway of GXST,and lays a certain foundation for further elucidation of the mechanism of GXST in the treatment of coronary heart disease.
作者
孙志
左莉华
师莹莹
周霖
李卓伦
冯娟娟
康建
贾清泉
蔡琦
张晓坚
SUN Zhi;ZUO Li-hua;SHI Ying-ying;ZHOU Lin;LI Zhuo-lun;FENG Juan-juan;KANG Jian;JIA Qing-quan;CAI Qi;ZHANG Xiao-jian(Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Laboratory of Accurate Clinical Pharmaceutical of Henan Province,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Rehabiliation Medicine,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Medical college,Henan Polytechnic University,Jiaozuo 454000,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2019年第3期200-207,共8页
Chinese Pharmaceutical Journal
基金
河南省重点研发与推广专项项目资助(182102310404)
常州四药临床药学科研基金资助(CZSYJJ16030)
关键词
冠心舒通胶囊
槲皮素
山柰酚
冠心病
靶点
信号通路
Guanxinshutong capsule
quercetin
raempferol
coronary heart disease
target
signaling pathway